Emmanuel Simon Email & Phone Number

Princeton, Nj, Us

Princeton, Nj, Us

The Woodlands, Tx, Us

Sr Dir - Market Development – Type 1 Diabetes with CKD and Heart Failure (Sept 2024 - Present)Amplified and accelerate the national and regional HCPs advocacy for Lexicon portfolio Helped the organization to grow by identifying new business opportunities/markets. Developing local strategies to enter them- Recruited and onboarded a Regional Marketing Lead team (new roles – Director level)- Set-up a plan to Identify and develop engaging plans at both the national and regional levels with key customers, including KOL, Local and Regional Influencers, Professional Societies and Advocacy Groups.Sr Dir – Cardiovascular marketing - Brand lead (Jul – Sep 2024)Dir – HCP marketing (Nov 2022 - Jul 2024)Led HCP marketing strategy to support the INPEFA launch (cardiovascular - Heart Failure)Developed the strategic direction, design, execution and measurement of all HCP oriented marketing strategies, tactics and activities to deliver on the INPEFA objectives- Developed and refine, Brand positioning, promotional messages for personal and non-personal engagements and assets. Made HCP PP assets/patient education materials available 3 weeks post PDUFA. Drove the branded campaign development- Set up a steering committee including 10 national Key Opinion Leaders, set up a speaker bureau (60 regional leaders) and developed and executed speaker programs (Advisory Board, expert theaters, National Broadcast, speaker programs…) – including developing scientific slide decks. 402 speaker programs completed in 2024; 3,173 attendees (95% were really satisfied with the quality of the programs).

Assisted business leaders leverage brand competitive advantage and amplify the brand(s) growth (website)Support the development of commercial strategies to navigate and respond effectively to market challenges. Revealed hidden insights that will help leaders to take key decisions with confidence. - Helped organization to clarify where to play— how to win—what to expect with fact-based evidences, facilitate the tactical plans development and/or design practical dashboards to track performance.

Bagsværd, Dk

Obesity HCP MarketingLaunched Semaglutide 2.4mg for Obesity – Wegovy™– A “game changer” (acc. to KOLs)Reached in 3 months a similar total volume with the in-market Novo Nordisk obesity medication without impacting its volume. Considered as the best launch (all brands) ever at Novo Nordisk in US. Prepared a robust HCP-P campaign to be launch 72h Post PDUFA (HCP-P) in a virtual contextDeveloped and implemented the first Pharmacy campaign for NNI Obesity portfolioIn a context of limited Market Access for Anti Obesity Medication, set up a clear and simple market access promotional campaign.Develop and manage Saxenda® Promotional StrategyExceeded sales executionCo-developed the Obesity BU strategic plan and Saxenda® brand strategyDeveloped plans for in depth market analysis and led advisory boardsPrepared Saxenda®/HCP strategy execution assessment and provided clear direction to sales force during POAs (Pharma sales force meetings)Led speaker program strategy recommendation through critical analysis and improved execution planIn context of life cycle management, optimized the promotion of label changes: leveraged a new CV indication and launched campaign for new adolescent indication

Bagsværd, Dk

Led Tresiba® market development, Market Access and Medical activitiesDeveloped Market Access communication for Tresiba® including via EHR systems to capture attention at the point of prescriptionLeveraged DEVOTE clinical study in speaker programs, making hypoglycemia/safety a key driver of brand preference Prepared Ryzodeg® business case to establish launch approach & optimized the Insulin Portfolio Strategy Led strategy development for the insulin portfolio based on a rigorous segmentation and profiling of customersSupported Faster insulin aspart: Fiasp® Launch (to replace NovoLog® $1.8b sales in USA) Co-led US strategy development and tactical planning for Fiasp® launch in collaboration with Global teamDeveloped HCP segmentation and marketing mix analysis to optimize the launch budget allocationConducted KOL ad-boardsDrove market development via HCP curriculum development, speaker programs, webcast, lunch & learn programsLed the Extended Brand Team to develop and implement a consistent, cross-functional approach to launch Fiasp®Accelerated patient conversion from Human Premix Insulin to NovoLog® Mix 70/30.Received NNI Marketing Award for "Inspiration" from a Diabetes Marketing Leader Led the NovoLog® Mix 70/30 Extended Brand TeamOvercame silo thinking across functions to deliver a strong team commitment behind this mature brandDesigned an advanced segmentation/targeting approach that inspired other NNI teams to maximize tactical plans and execution

Bagsværd, Dk

Develop and execute Intensification Strategy with NovoRapid® for Type 2 diabetesCross functional projects lead. Accelerate upgrade from human insulin to modern insulin and devices mainly in North America, Germany, East EU, Emerging Markets (India, Africa, Gulf).

Bagsværd, Dk

Strenghtened NovoRapid® and NovoMix® #1 positionSet up "Insulin and Pregnancy" and "Insulin and emergency" advisory boardsLaunch the 1st Novo Nordisk University program (CME)Rised up NovoFine Autocover sales +30% MS at hospital

Bagsværd, Dk

Re-launch the Novo Nordisk Information Service: +110% interactions with HCPDeveloped the first « on line » congress report in diabetology - reach out to 85% of targeted stakeholders - Lead experts and medical writers meetings

Paris, Fr

Master, Chaire Essec Santé - Mia

Master'S Degree, Biochemistry - Neurosciences